In the Media
Nonviral Platforms Streamline Gene Therapy Delivery 150 150 Eyevensys

Nonviral Platforms Streamline Gene Therapy Delivery

Korea Investment Partners is leading the Series B Plus financing and existing investors will also join the round, reports Pharmtech Focus.

ARVO 2023: Eyevensys announces positive preclinical data demonstrating efficacy of EYS809 over aflibercept for wet AMD 150 150 Eyevensys

ARVO 2023: Eyevensys announces positive preclinical data demonstrating efficacy of EYS809 over aflibercept for wet AMD

Korea Investment Partners is leading the Series B Plus financing and existing investors will also join the round, reports Pharmtech Focus.

Pharmtech Focus: Eyevensys Raises $12M in a Series B Plus Funding Round 150 150 Eyevensys

Pharmtech Focus: Eyevensys Raises $12M in a Series B Plus Funding Round

Korea Investment Partners is leading the Series B Plus financing and existing investors will also join the round, reports Pharmtech Focus.

WSJ Pro VC Daily: Biotech Acquisitions Could Be Poised for Second-Half Rebound 150 150 Eyevensys

WSJ Pro VC Daily: Biotech Acquisitions Could Be Poised for Second-Half Rebound

Eyevensys, a developer of therapies for ophthalmic diseases raised $12 million in Series B+ funding.

GeneTherapyLive: Non-Viral Gene Therapy Eases Treatment Burden in Wet AMD 150 150 Eyevensys

GeneTherapyLive: Non-Viral Gene Therapy Eases Treatment Burden in Wet AMD

A non-viral gene therapy sustained drug-delivery product that delivers anti-VEGF to the eye may replace the need for repeated intravitreal anti-VEGF injections and improve vision in patients with wet AMD.

Can Gene Therapy Cure Blindness? 150 150 Eyevensys

Can Gene Therapy Cure Blindness?

LABIOTECH.eu reports on Eyevensys and other innovative companies developing gene therapy treatments with the potential to cure different forms of genetic blindness.

Women Worldwide Podcast: How Are You Innovating in Your Role? 150 150 Eyevensys

Women Worldwide Podcast: How Are You Innovating in Your Role?

Eyevensys CEO, Patricia Zilliox, discusses innovation as a key component of growth in the medical and pharmaceutical industry, what her work has taught her about fundraising, and the impact of the pandemic on her work.

OIS: Francine Behar-Cohen Presents “Innovative Non-Viral Therapies for the Treatment of Ocular Diseases” 150 150 Eyevensys

OIS: Francine Behar-Cohen Presents “Innovative Non-Viral Therapies for the Treatment of Ocular Diseases”

Watch Eyevensys Founder and Chief Innovation Officer, Prof. Francine Behar-Cohen, present at the OIS Ocular Drug Delivery Meeting, providing details about our innovative non-viral gene therapies for the treatment of ocular diseases and our active pipeline and strategy.

Le Figaro: Eyevensys, the Ray of Hope for Treating Ophthalmological Diseases 150 150 Eyevensys

Le Figaro: Eyevensys, the Ray of Hope for Treating Ophthalmological Diseases

Eyevensys founder, Francine Behar-Cohen, and Scientific Director, Thierry Bordet talk to Le Figaro about the company’s innovative treatments and technology in development for treating eye diseases. (article and video)

OIS: Eyevensys CEO, Patricia Zilliox, Featured on OIS Retina Podcast 150 150 Eyevensys

OIS: Eyevensys CEO, Patricia Zilliox, Featured on OIS Retina Podcast

Listen to Patricia Zilliox, CEO of Eyevensys, discuss her background, her industry experience and expertise, and her passion for developing treatments to improve patient outcomes.

  • 1
  • 2